Jane Street’s Cogent Biosciences COGT Stock Holding History

Jane Street’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.78M	Sell	149,400 -27,400	-15%	-$959K	﹤0.01%	3501
2026 Q1	$6.81M	Buy	176,800 +41,500	+31%	+$1.53M	﹤0.01%	3062
2025 Q4	$4.81M	Buy	135,300 +121,600	+888%	+$3.42M	﹤0.01%	3286
2025 Q3	$197K	Buy	+13,700	New	+$162K	﹤0.01%	9699
2022 Q3	–	Sell	-58,600	Closed	-$529K	–	9776
2022 Q2	$529K	Buy	+58,600	New	+$400K	﹤0.01%	6625

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Jane Street's COGT Position: Q2 2026 in Review

Jane Street sold out of Cogent Biosciences (COGT) in Q2 2026, closing a stake of 5,483 shares — an estimated $192K sold.

Jane Street first reported a position in COGT in Q3 2018 and held it in 15 quarters. The position peaked at $2.13M in Q3 2025. 324 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

Jane Street reported no remaining Cogent Biosciences position as of Q2 2026 after selling out during the quarter.
Jane Street sold 5,483 Cogent Biosciences shares in Q2 2026, an estimated $192K.
Jane Street first reported a position in Cogent Biosciences in Q3 2018 and held it in 15 quarters.
Jane Street's Cogent Biosciences position peaked at $2.13M in Q3 2025.
324 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.